R&D News | pharmaphorum

News

Image of a pair of lungs on an orange-beige background

Pfizer's Seagen-derived ADC pipeline suffers a setback

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

News

MSD's TL1A drug tulisokibart delivers in pivotal IBD trial

MSD's tulisokibart has become the first anti-TL1A antibody to help patients with ulcerative colitis achieve clinical remission in a phase 3 trial.

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

News

Boehringer advances duo for aggressive cancers into phase 3

Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.

News

Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance

Insilico Medicine has teamed up with SK Biopharmaceuticals on a wide-ranging, $2.5bn partnership to use AI to find neuroimmune drug candidates.

News

Sanofi names ex-Roche exec Fontoura as R&D chief

Paulo Fontoura, currently chief medical officer of Xaira Therapeutics, will replace Houmab Ashrafian as Sanofi's R&D head on 1st September.

Pfizer's Seagen-derived ADC pipeline suffers a setback

MSD's TL1A drug tulisokibart delivers in pivotal IBD trial

AbbVie climbs post-Allergan M&A peak with Apogee buy

Boehringer advances duo for aggressive cancers into phase 3

Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance

Sanofi names ex-Roche exec Fontoura as R&D chief

PMV cues up filing for first p53-directed cancer therapy

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks